DRUG INTERACTION IN PROLANIS PATIENT IN ONE PRIVATE HOSPITAL IN BANDUNG IN THE PERIOD OF JANUARY –MARCH 2021

• Main Author: Risfayanti, Iffa
• Format: Theses
• Language: Indonesia
• Online Access: https://digilib.itb.ac.id/gdl/view/56439
• Institution: Institut Teknologi Bandung

The Chronic Disease Management Program (Prolanis) is a health service system with a proactive approach implemented in an integrated manner under BPJS Kesehatan supervision. This program aims to encourage patients with chronic diseases, in this case, patients with type-2 diabetes mellitus and / or hypertension. to achieve optimal quality of life. Prescription of more than one drug to patients with chronic diseases such as hypertension and type-2 diabetes mellitus—which is the target of Prolanis, is common and it is generally associated with potential drug interactions that can occur in the patient. In Indonesia, research related to drug interactions in Prolanis patients is still limited and only involves the geriatric patient. This study aims to determine the description of drug interactions in Prolanis patients treated at the Muhammadiyah Hospital Bandung for the period January - March 2021, and to determine the correlation between the incidence of polypharmacy and potential drug interactions that can occur in Prolanis patients. This study involved 1354 patients and carried out a comparative analysis between group without drug interactions and group with drug interactions. There are 1092 patients (80.65%) who are indicated to have one or more potential drug interactions from 1354 patients whose prescription data were taken. The incidence of drug interactions was 3.3 drug interactions / prescription sheets in the drug interaction group. The types of drug interactions with the most potential to occur are drug-drug interactions with moderate and major severity, as well as with the type of pharmacodynamic interactions. There was a strong association between the incidence of polypharmacy and the presence of potential drug interactions in Prolanis patients (r = 0.394, p <0.01) as well as a significant difference about the presence of potential drug interactions between the poilipharmacy and non-polypharmacy groups (p <0.001).